Heart failure affects millions of people worldwide and can significantly impact quality of life. Research into new treatment approaches remains critical to improving outcomes and expanding options for patients living wit...

Colleagues at our Mexico office put their gaming skills to the test earlier this month at the ICON4U Super Smash Bros. Ultimate Tournament. Organised by the ICON4U Engagement and Celebrations Chapter, the event welcomed...

ctDNA holds significant potential for accelerating cancer drug development, but acceptance as a primary surrogate endpoint remains a major regulatory challenge. ICON’s Bea Mann examines the scientific, regulatory and evi...

Modern Alzheimer's management requires an "MRI metronome". For anti-amyloid therapies, rigid adherence to routine MRI schedules is essential to detect dangerous amyloid-related imaging abnormalities (ARIA). Read our arti...

Talent shortages are emerging as a critical challenge for Asia-Pacific biotech companies. A recent ICON survey found that biotech professionals in APAC were nearly three times more likely than their global peers to repor...

Latest issue now available. Join thousands of subscribers who have discovered the convenience of our free monthly publication, by signing up today. https://ow.ly/hTYQ50Zu7sT Compiled and collated by ICON’s Regulatory I...

Accelerated approval is not a shortcut – it is a strategic decision that demands robust planning. In this latest Drug & Device World article, ICON’s Elizabeth Madichie and Jack Martin highlight why surrogate endpoints m...

As more innovative therapies emerge from the APAC region, sponsors seeking global approval face increasingly complex regulatory decisions. Our latest article in PharmaTimes Magazine examines key considerations for navig...

When Alyssa Gilliam joined ICON as a Clinical Trial Assistant in 1998, she expected it to be a temporary step. It became the start of a career shaped by new challenges, strong relationships and a willingness to keep lear...

Global clinical development is entering a more connected, data-driven era. While the FDA is piloting real-time clinical trials, other regulatory bodies are advancing AI and digital strategies in different ways, creating...

Patient safety starts long before the first neurologic mAb dose. Indication-specific safety planning and strict patient stratification are vital, from HBV screening in MS to AQP4 status in NMOSD. Read the article to dive...

If you've ever searched for pharmacovigilance and wondered what it actually means, you're not alone. While roles like Clinical Research Associate are widely recognised, pharmacovigilance is often less understood. Yet it...